Nov. 15 at 3:10 AM
$ATAI It's all about market cap comparisons...not SP...given the dilution associated with the Beckley merger and separate capital raise...but if you just compare market caps...Atai was at
$1.51B on 10/17 when the SP closed at
$6.45, and Atai's market cap currently sits just under
$1.5B with a SP of
$4. The key difference is Atai now has sufficient capital to get BPL-003 through phase 3 and likely through FDA approval...at which point that market cap will jump considerably...interim dilution is never fun...but unfortunately it's a necessary part of the game for pre-rev biotech. Stay long, stay confident...we'll look up and see a market cap of
$10-
$20B in the next 3-5 years.
